Table 1.
Relationship between the pretreatment ADR and clinicopathological factors.
| Total | Low-ADR | High-ADR | P value | |
|---|---|---|---|---|
| Total (n) | 247 | 86 | 161 | |
| Age (years) | 59 (52–64) | 58 (51–62) | 60 (52–65) | 0.102 |
| Sex (n) | ||||
| Male | 163 (66.0%) | 56 (65.1%) | 107 (66.5%) | 0.832 |
| Female | 84 (34.0%) | 30 (34.9%) | 54 (33.5%) | |
| Body mass index (kg/m2) | 21.51 (19.57–23.43) | 20.76 (19.34–23.63) | 21.97 (19.79–23.27) | 0.565 |
|
| ||||
| ECOG PS score (n) | ||||
| 0-1 | 209 (84.6%) | 73 (84.9%) | 136 (84.5%) | 0.932 |
| ≥2 | 38 (15.4%) | 13 (15.1%) | 25 (15.5%) | |
|
| ||||
| Pathological differentiation (n) | ||||
| Well | 67 (27.1%) | 15 (17.4%) | 52 (32.3%) | 0.012 |
| Poorly | 180 (72.9%) | 71 (82.6%) | 109 (67.7%) | |
|
| ||||
| The number of organs affected by metastasis (n) | ||||
| 0-1 | 160 (64.8%) | 50 (58.1%) | 110 (68.3%) | 0.110 |
| ≥2 | 87 (35.2%) | 36 (41.9%) | 51 (31.7%) | |
|
| ||||
| Peritoneal metastasis (n) | ||||
| Yes | 75 (30.4%) | 35 (40.7%) | 40 (24.8%) | 0.010 |
| No | 172 (69.6%) | 51 (59.3%) | 121 (75.2%) | |
|
| ||||
| TNM stage (n) | ||||
| III | 51 (20.6%) | 11 (12.8%) | 40 (24.8%) | 0.026 |
| IV | 196 (79.4%) | 75 (87.2%) | 121 (75.2%) | |
| Thrombocyte counts (×109/L) | 257 (193–341) | 269 (210–350) | 247 (184–325) | 0.031 |
| Hemoglobin (g/L) | 123.0 (106.0–139.0) | 120.5 (104.5–134.3) | 125.0 (106.5–139.0) | 0.083 |
| CEA (ng/mL) | 3.60 (1.55–11.31) | 4.66 (1.73–18.60) | 2.97 (1.52–9.24) | 0.173 |
| CA19-9 (U/mL) | 19.60 (7.94–111.90) | 20.86 (8.79–124.53) | 17.12 (7.84–95.39) | 0.446 |
| CA72-4 (U/mL) | 7.52 (2.55–26.53) | 12.13 (4.28–45.69) | 5.19 (2.19–21.35) | 0.001 |
ADR, albumin to D-dimer ratio; ECOG PS, Eastern Cooperative Oncology Group performance status; CEA, carcinoembryonic antigen; CA72-4, carbohydrate antigen 72-4; CA19-9, carbohydrate antigen 19-9.